Citi Starts Voyager Therapeutics (VYGR) at Buy, 'premier player'

Citi analyst David Hoang initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Buy rating and a price target of $16.00.

The analyst comments "VYGR shares are up ~26% over the past month (vs. XBI +13%), as the market gains a greater appreciation of the company’s capabilities in the CNS space following recent deal activity with Novartis in January. After a strategic shift in 2021 and under leadership of CEO Al Sandrock (ex-Biogen) since March 2022, “VYGR 2.0” has emerged as a premier player in CNS gene therapies with its proprietary TRACER platform and next-gen AAV capsids, backed by a strong balance sheet. We value VYGR’s pipeline of wholly-owned and partnered assets using a risk-adjusted DCF. Initiate Buy/High Risk, $16 TP."

For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.

Shares of Voyager Therapeutics closed at $9.10 yesterday.

You May Also Be Interested In

• Clear Street Starts Q32 Bio Inc. (QTTB) at Buy
• DA Davidson Starts C&F Financial Corp. (CFFI) at Buy
• Raymond James Assumes HCA Healthcare Inc (HCA) at Market Perform